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Abstract
TH17 cells have been implicated in a growing list of inflammatory disorders. Antagonism of TH17 cells can be used for the
treatment of inflammatory injury. Currently, very little is known about the natural compound controlling the differentiation
of TH17 cells. Here, we showed that Baicalin, a compound isolated from a Chinese herb, inhibited TH17 cell differentiation
both in vitro and in vivo. Baicalin might inhibit newly generated TH17 cells via reducing RORct expression, and together with
up-regulating Foxp3 expression to suppress RORct-mediated IL-17 expression in established TH17 cells. In vivo treatment
with Baicalin could inhibit TH17 cell differentiation, restrain TH17 cells infiltration into kidney, and protect MRL/lpr mice
against nephritis. Our findings not only demonstrate that Baicalin could control TH17 cell differentiation but also suggest
that Baicalin might be a promising therapeutic agent for the treatment of TH17 cells-mediated inflammatory diseases.
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Introduction
The T helper 17 (TH17) lineage, a lineage of effector CD4
+ T
cells characterized by production of interleukin (IL)-17, is
described based on developmental and functional features distinct
from classical TH1 and TH2 lineages [1,2]. TH17 cells are
associated with the development and pathogenesis of a growing list
of chronic inflammatory diseases, including rheumatic arthritis,
psoriasis, atopic dermatitis, and asthma [3,4,5]. Our studies, as
well as others, have shown that TH17 cells also play a key role in
the pathogenesis of systemic lupus erythematosus (SLE)
[6,7,8,9,10,11]. Several studies have advocated that TH17 cells
might be a promising therapeutic target for chronic inflammatory
injury [12,13].
The differentiation of TH17 cells is initiated by transforming
growth factor-b (TGF-b) and interleukin-6 (IL-6) in mice, and
interleukin-23 (IL-23) is also required [14]. Signal transduction
and activator of transcription 3 (STAT3), aryl hydrocarbon
receptor (AHR) and the retinoic acid-receptor-related orphan
receptor-ct (RORct) mediate TH17 lineage commitment
[15,16,17]. Several studies have indicated that 2,3,7,8-tetrachlo-
rodibenzo-p-dioxin (TCDD), halofuginone, and retinoic acid
could suppress the expression of these transcription factors, and
subsequently inhibit the differentiation of TH17 cells [18,19,20].
However, few natural compounds restraining TH17 cells are
known. Moreover, it is important to explore not only effective but
also safe therapeutic agents for the treatment of TH17 cells-
mediated inflammatory injuries.
Baicalin, which is a main active ingredient originally isolated
from the root of Huangqin (Scutellaria baicalensis Georgi), has
safety records in clinic and has been used as an anti-inflammatory
drug in traditional Chinese medicine [21,22]. Previous studies
have showed that Baicalin could inhibit the proliferation of
mononuclear cells, inhibit macrophage activation, inhibit the
production of TH1 related cytokines in different disease murine
models [23,24]. Baicalin was shown to reduce the severity of
experimental autoimmune encephalomyelitis (EAE) [23]. Since
TH17 cells are important inducer of EAE, we hypothesized that
Baicalin might inhibit inflammatory injuries by suppressing
effector TH17 cells. Furthermore, previously published data
confirmed that Baicalin inhibited the activation of AHR [25],
which might has relevance to the proposed effect on TH17 cell
development.
In this study, we observed that Baicalin inhibited TH17 cell
differentiation in vitro. Detailed studies showed that Baicalin
might inhibit newly generated TH17 cells via suppressing RORct
expression, and together with up-regulating Foxp3 expression to
suppress RORct-mediated IL-17 expression in established TH17
cells. Baicalin could inhibit the generation of TH17 cells in vivo,
reduce TH17 cells infiltration into kidney via inhibition of the
CCL20-CCR6 signaling pathway, and could protect lupus-prone
MRL/lpr mice against nephritis. Taken together, these findings
suggest that Baicalin might be a promising therapeutic agent for
the treatment of TH17 cells-mediated inflammatory diseases.
Results
Baicalin inhibits TH17 cell differentiation in vitro
Baicalin (7-glucuronic acid, 5, 6-dihydroxyflavone, molecular
weight =446.36. Figure S1A) is a flavonoid compound originally
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Georgi). First, using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylte-
trazolium bromide (MTT) and flow cytometry, we observed that
treatment with 20 mM Baicalin did not result in generalized
inhibition of T cell proliferation and cell cycle (Figure S1B and C),
thus 20 mM Baicalin was used in most in vitro experiments. To
determine whether Baicalin controls the differentiation of TH17
cells, CD4
+CD25
2 T cells from B6 mice were isolated. Under
TH17 culture conditions (TGF-b plus IL-6 stimulation), IL-17
mRNA expression was increased 2.9-fold compared to control
cells on day 2 and 10.7-fold compared to control cells on day 3.
Following addition of 20 mM Baicalin to the culture, IL-17 mRNA
expression was inhibited. In fact, IL-17 expression was decreased
to 1.2-fold on day 2 and 2.5-fold on day 3 compared to controls
(Figure 1A). In addition, 20 mM Baicalin measurably inhibited IL-
17 protein secretion (Figure 1B). We further proved that the
suppression of TH17 cell differentiation was dependent on the dose
of Baicalin (Figure 1C). These results provide evidence that
Baicalin can suppress the development of TH17 cells.
Baicalin inhibits IL-6 receptor and RORct mRNA
expression
IL-6, an acute-phase protein induced during inflammation, may
‘‘dictate’’ TH17 cell differentiation [26]. Thus, we next determine
whether Baicalin-mediated inhibition of TH17 cell differentiation is
IL-6-dependent. CD4
+CD25
2 T cells from B6 mice were
stimulated with anti-CD3, anti-CD28, and the indicated cytokines
inthe presenceorabsenceofBaicalin.IL-6receptor(IL-6R) mRNA
expression was analyzed by real-time RT-PCR at the indicated
times. As expected, IL-6R mRNA was suppressed by Baicalin
(Figure 2A). Further study confirmed that Baicalin could reduce IL-
6R protein expression during Th17 cell differentiation (Figure 2B).
RORct, which is a key transcription factor involved in TH17 cell
differentiation, is elicited by IL-6 and TGF-b [17]. During TH17
cell differentiation in vitro, addition of Baicalin reduced RORct
expression (Figure 2C). IL-23 expands the pool of TH17 cells [27],
but Baicalin failed to affect the expression of IL-23 receptor during
TH17 differentiation (Figure S2A). TGF-b and IL-21 can induce
STAT3-mediated IL-17 expression during TH17 differentiation
[16], while Baicalin did not restrain IL-21-induced STAT3 and IL-
17 mRNA expression during TH17 cell differentiation (Figure S2B
and 2C). These data suggest that Baicalin could reduce IL-6R and
RORct expression during TH17 cell differentiation, which imply
that Baiclain might suppress de novo TH17 cell differentiation via
inhibition of IL-6-mediated RORct expression.
Baicalin up-regulates Foxp3 and down-regulates RORct-
meidated IL-17 expression
TGF-b induces the differentiation of Treg cells, whereas TGF-b
in combination with IL-6 results in the differentiation of TH17
Figure 1. Baicalin inhibits TH17 cell differentiation in vitro. (A) CD4
+CD25
2 T cells from B6 mice were stimulated with anti-CD3, anti-CD28,
and the indicated cytokines in the presence (open columns) or absence (filled columns) of Baicalin. IL-17 mRNA was analyzed by real-time RT-PCR at
the indicated times. Results were expressed as mean 6 SD, and fold induction compared with vehicle control (expression in vehicle control was set as
1.0). (B) IL-17 was examined by ELISA in culture supernatants after 3 days activation. Results were expressed as mean 6 SD, and compared with
vehicle control. (C) CD4
+CD25
2 T cells were cultured under TH17 conditions in the presence of indicated doses of Baicalin for 3 days, and then re-
stimulated with PMA and Ionomycin in the presence of Brefeldin A for 5 hours. The percentages of IL-17
+ cells among CD4
+ T cells were examined by
flow cytometry. These experiments were performed three times with similar results.
doi:10.1371/journal.pone.0017164.g001
Control of TH17 Cell Differentiation by Baicalin
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+CD25
2 T cells from B6 mice were stimulated
with anti-CD3, anti-CD28, and the indicated cytokines, after 2
days stimulation, 20 mM Baicalin was added for additional 2 days.
Foxp3 and IL-17 intracellular expression in CD4
+ T cells were
determined by flow cytometry. Surprisingly, T cells cultured with
Baicalin under conditions that otherwise promoted IL-6-depen-
dent TH17 cell differentiation converted to Foxp3
+ T cells with a
concomitant decrease in TH17 cell differentiation (Figure 3A). In
addition, Baicalin could inhibit RORct-mediated IL-17 mRNA
expression in established TH17 cells (Figure S3A). Thus, we
hypothesized that Baicalin could inhibit RORct transcriptional
activity partly via up-regulation of endogenous Foxp3 expression,
because previous report showed that Foxp3 could inhibit RORct-
mediated IL-17 expression and TH17 cell differentiation [29]. To
support this hypothesis, we further showed that Baicalin in synergy
with TGF-b could up-regulate endogenous Foxp3 expression in
CD4
+CD25
2 T cells (Figure S3B), Baicalin could promote
endogenous Foxp3 expression (Figure 3B, middle panel) and
reduce RORct expression during TH17 cell differentiation
(Figure 3B, upper panel), and Baicalin together with forced
expression of Foxp3 could inhibit RORct and IL-17 mRNA
expression during TH17 cell differentiation (Figure 3C). Collec-
tively, these data imply that Baicalin could inhibit RORct
expression in established TH17 cells, together with up-regulating
Foxp3 inhibit RORct-mediated IL-17 expression.
Baicalin inhibits TH17 cell differentiation in vivo
To determine whether Baicalin controls the development of TH17
cells in vivo, lupus-prone MRL/lpr mice were treated with Baicalin or
vehicle for nine weeks. Notably, mice without Baicalin treatment
developed severe nephritis with increased urine protein, while mice
receiving Baicalin were protected against nephritis with decreased
urine protein (Figure 4A-C). Baicalin also protected the survival and
liver function of MRL/lpr mice (Table 1 and Figure S4). Furthermore,
Baicalin reduced the spleen index and inhibited differentiation of TH17
cells in spleens (Figure 4D-F). Interestingly, Baicalin only slightly
affected the frequency of Treg cells in vivo (Figure 4F).
Further study showed that Baicalin reduced the infiltration of
TH17 cells into the kidneys (Figure 5A). Inflamed tissue produces
CCL20 to facilitate the migration of CCR6-expressing TH17 cells
to the inflamed tissues [30,31]. Baicalin treatment inhibited
CCL20 mRNA expression in kidneys and CCR6 expression in
TH17 cells (Figure 5B and C), which indicated that Baicalin might
interfere TH17 cell infiltration into kidneys via inhibition of the
CCL20-CCR6 expression.
Baicalin inhibits IL-17 mediated gene expression of
inflammatory molecules
IL-17 acts as a potent inflammatory cytokine, and mediates
leukocyte infiltration and tissue destruction [2,32]. Baicalin
inhibited expression of genes encoding inflammatory molecules
(ICAM-1, VCAM-1, and IL-17) in HUVEC that were induced by
exogenous IL-17 (Figure 6A). In support of these results, Baicalin
reduced IL-17-induced adhesion of T cells to HUVEC (Figure 6B).
In addition, Baicalin also suppressed gene expression of inflam-
matory mediators in MRL/lpr mouse kidney (Figure S5).
Together, these data indicate that Baicalin could partially inhibit
IL-17-induced inflammation.
Figure 2. Baicalin inhibits IL-6R and RORct mRNA expression. (A) CD4
+CD25
2 T cells from B6 mice were stimulated with anti-CD3, anti-CD28,
and the indicated cytokines in the presence (open columns) or absence (filled columns) of Baicalin. IL-6R mRNA expression was analyzed by real-time
RT-PCR at the indicated times. Results were expressed as mean 6 SD, and fold induction compared with vehicle control (expression in vehicle control
was set as 1.0). (B) CD4
+CD25
2 T cells were cultured under the indicated cytokines with or without 20 mM Baicalin for 2 days, IL-6R protein was
measured by western blot analysis. (C) RORct mRNA expression was analyzed by real-time RT-PCR at the indicated times. Results were expressed as
mean 6 SD, and fold induction compared with vehicle control (expression in vehicle control was set as 1.0). These experiments were performed three
times with similar results.
doi:10.1371/journal.pone.0017164.g002
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Baicalin, which is a main active ingredient originally isolated
from the root of Huangqin (Scutellaria baicalensis Georgi), has
safety records in clinic and has been used as an anti-inflammatory
drug in traditional Chinese medicine [21]. Baicalin has been found
to possess anti-inflammatory, antioxidant and anti-allergic prop-
erties, and appears to contribute to the treatment of chronic
inflammatory diseases, including hepatitis, allergic diseases, and
EAE [22,23,33].
The binding of IL-6 with IL-6R plays a key role in the
transcription of RORct during the development of TH17 cells,
and IL-6 blockade by treatment with an anti-IL-6R monoclonal
antibody might inhibit the development of TH17 cells [34,35]. IL-
6-deficient mice do not express RORct and IL-17 [17]. Together,
these data suggest that IL-6 is a key cytokine to induce the
expression of RORct and the development of TH17 cells. Our
data showed that Baicalin treatment inhibited the expression of
IL-6R and RORct under culture conditions promoting TH17 cell
differentiation. However, the down-regulation of IL-6R was not
accompanied by decreased expression of STAT3. IL-21 is also a
key cytokine for STAT3-mediated TH17 cell differentiation [16],
Baicalin did not suppress IL-21R and STAT3 mRNA expression
induced by TGF-b and IL-6 (Figure S2A), which might explain
that reduced expression of IL-6R was not accompanied by
decreased mRNA expression of STAT3. Baicalin also hardly
restrain IL-21-induced STAT3 and IL-17 mRNA expression
during TH17 cell differentiation (Figure S2B and C). But Baicalin
could affect the STAT3 phosphorylation induced by TGF-b and
IL-6 (Figure S2D). Thus, these data implied that transcript levels
of STAT3 did not mirror protein levels, and Baicalin might
regulate TH17 cell differentiation by affecting STAT3 phosphor-
ylation but not the expression of STAT3. Furthermore, cytokine
receptors like IL-4R and IL-12Rb2 have negative impacts on
TH17 cell differentiation, our supplemental data showed that
20 mM Baicalin did not affect the mRNA expression of IL-4R and
IL-12Rb2 during TH17 cell differentiation (Figure S2A). These
data implied that Baicalin might restrain de novo TH17 cell
differentiation by abrogating IL-6 mediated RORct transcription,
and Baicalin-mediated inhibition of STAT3 activation might
contribute to reduced STAT3-mediated gene expression, such as
RORct and IL-17A [36].
Figure 3. Baicalin up-regulates Foxp3 and down-regulates RORct expression. (A) CD4
+CD25
2 T cells from B6 mice were stimulated with
anti-CD3, anti-CD28, and the indicated cytokines, after 2 days stimulation, Baicalin was added for additional 2 days. The percentages of Foxp3
+ and IL-
17
+ cells among CD4
+ T cells were determined by flow cytometry. (B) CD4
+CD25
2 T cells from B6 mice were stimulated with anti-CD3, anti-CD28, and
the indicated cytokines, after 2 days stimulation, Baicalin was added for additional 2 days. Foxp3 and RORct mRNA expression were examined by RT-
PCR. (C) CD4
+CD25
2 T cells from B6 mice were cultured under TH17 conditions for 2 days and then transiently transfected with control plasmids
(Control) or Foxp3 expression plasmids (Foxp3) in the presence or absence of Baicalin. 2 days later, RORct, IL-17, and Foxp3 mRNA were examined by
RT-PCR.
doi:10.1371/journal.pone.0017164.g003
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[14,27,37]. Although Baicalin did not affect IL-23 receptor mRNA
expression during TH17 cell differentiation, Baicalin, when added
2 days after initiation of TH17 cultures, also inhibited differenti-
ation of TH17 cells. We first confirmed that Baicalin could inhibit
RORct-mediated IL-17 mRNA expression in established TH17
cells (Figure S3A), which might partly stem from the block in IL-
6R signaling in TH17 cells. We further detected that Baicalin not
only inhibited IL-17 expression but also up-regulated Foxp3
expression (Figure 3A), thus we hypothesized that Baicalin-
induced Foxp3 expression might exert inhibition on RORct-
mediated IL-17 expression during TH17 cell differentiation.
Because previous study has proved that Foxp3 could interact with
RORct and inhibit RORc-directed IL-17 expression during TH17
cell differentiation [29]. To support this hypothesis, we showed
that Baicalin together TGF-b could up-regulate endogenous
Foxp3 mRNA and down-regulate RORct mRNA expression
(Figure 3A, B, and Figure S3B). In addition, exogenous over
expressed Foxp3 could inhibit RORct-mediated IL-17 mRNA
expression in TH17 cells, Baicalin together with Foxp3 might
augment inhibition of IL-17 mRNA expression (Figure 3C).
Interestingly, we also noticed that RORct mRNA expression was
also inhibited by forced expression of Foxp3, and Baicalin together
with exogenous Foxp3 have a additive inhibition of RORct
expression (Figure 3C). Whereas further study should be
performed to make clear the mechanism of Foxp3-mediated
inhibition of RORct expression. All together, these data implied
that Baicalin could up-regulate Foxp3 expression and suppress
RORct-mediated IL-17 expression in established TH17 cells.
In our study, we unexpectedly found that Baicalin not only
inhibited the differentiation of TH17 cells but also promoted TGF-
b-mediated differentiation of Treg cells in vitro. Thus, Baicalin
Figure 4. Baicalin inhibits TH17 cell differentiation in vivo. (A) MRL/lpr mice were treated with Baicalin or vehicle for 9 weeks, B6 mice
(control) were treated with vehicle. Relative urine protein increases = urine protein (mg/L) at indicated time point - urine protein (mg/L) of week 0
(n=6 for each group). In the comparison between Baicalin- and vehicle-treated mice, the asterisk indicates p,0.001. (B) Histopathology of kidneys.
Hematoxylin and eosin staining (H&E, left) and periodic acid-Sciff-staining (PAS, right). Scale bar, 100 mm. (C) The renal score of control and MRL/lpr
mice (n=6 for each group). (D) Spleen index of control and MRL/lpr mice (n=6 for each group). (E) IL-6R and RORct mRNA levels in spleen cells of
MRL/lpr mice were analyzed by RT-PCR. (F) The percentages of IL-17
+ and Foxp3
+ cells among CD4
+ T cells of spleen cells isolated from MRL/lpr mice
were determined by flow cytometry analysis. (n=6 for each group). Results were expressed as mean 6 SD. Spleens were shown.
doi:10.1371/journal.pone.0017164.g004
Table 1. Survival data in MRL/lpr mice and B6 control.
Group Survival
Control 6 of 6 (100%)
Vehicle 6 of 9 (66.7%)
Baicalin 6 of 7 (85.7%)
MRL/lpr mice were treated with Baicalin or vehicle for 9 weeks, B6 mice (control)
were treated with vehicle.
doi:10.1371/journal.pone.0017164.t001
Control of TH17 Cell Differentiation by Baicalin
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a reciprocal balance of Foxp3 and RORct. IL-6 is a key cytokine
to inhibit Foxp3 expression during Treg cell differentiation [19],
inhibition of IL-6R expression could increase Treg cell differen-
tiation [38] Thus, Baicalin might induce Foxp3 expression by
restoring IL-6-mediated inhibition of Foxp3 expression in vitro. In
contrast to the observation that Baicalin enhanced Foxp3
expression in vitro, Baicalin treatment in MRL/lpr mice only
slightly affected CD4
+Foxp3
+ T cells. This minor expansion of
Foxp3
+ T cells might stem from the strong inhibition of excessive
inflammatory cytokines and lack of TGF-b in vivo [38,39,40].
Although we observed that 20 mM Baicalin did not affect cytokines
expression during the differentiation of TH1 and TH2 cells in vitro
(Figure S6), further study should be done to explore different
concentrations of Baicalin on the differentiation of TH1 and TH2
cells.
The number of TH17 cells was found to be increased in murine
model of SLE, including BXD2 [41], SNF1 [42], NZB6NZW F1
[43,44], and Ro52 knockout mice [45]. Our previous studies, as
well as others, showed that there were expansion of TH17 cells in
MRL/lpr mice [9,46,47]. Our unpublished data also showed that
treatment with anti-IL-17 antibody could protect MRL/lpr mice
against disease onset. Together, these data suggested that TH17
cells might play a key role in the pathogenesis of MRL/lpr mice.
Here we observed that Baicalin could reduce IL-6R and RORct
mRNA expression in spleens of MRL/lpr mice (Figure 4E), and
Baicalin could accordingly inhibit TH17 cell differentiation in vivo
(Figure 4F). These results were consistent with in vitro study of
Baicalin on the differentiation of TH17 cells. Interestingly, we
noticed that a high percentage of IL-17 producers was CD4
2 cells
in MRL/lpr mice (Figure 4F). Actually, TH17 cells (CD4
+IL-17
+ T
cells) are main source of IL-17 during chronic inflammatory
responses. However, in mice other subsets can also express IL-17,
including CD8
+ T cells, invariant natural killer T (NKT) cells, and
cd T cells [48,49,50,51]. Thus, we hypothesized that CD4
2L-17
+
cells were also expanded in MRL/lpr mice duo to severe
inflammatory responses, but further study should be performed
to dissect the specific source and function of these groups of
CD4
2L-17
+ cells.
Our data showed that Baicalin not only inhibited the differenti-
ation of TH17 cells in spleen but also reduced the infiltration of TH17
cells into kidney, which might result from inhibition of the CCL20-
CCR6 signaling pathway, since expression of CCL20 and CCR6
mRNA was found to be down-regulated by Baicalin. IL-17 is a key
TH17 cell-derived cytokine, which is implicated in leukocyte
recruitment [32]. Treatment with Baicalin couldsuppress production
of IL-17-mediated adhesion of T cells to HUVEC. Our in vivo
studies further confirmed that Baicalin could inhibit IL-17-related
inflammatory mediators, such as IL-22, IL-1, TNF-a,V C A M - 1 ,a n d
ICAM-1 (Figure S5A). Through the potent inhibition of these
adhesion molecules and inflammatory mediators, Baicalin might
further impede the recruitment of TH1, TH2 or other effector cells in
vivo. Thus, we are not making conclusions on the observed inhibition
of TH17 cells as the only function of Baicalin in vivo. Further study
should be done to dissect the other specific subsets of effector cells
affected by Baicalin in MRL/lpr mice. In addition, our unpublished
data also showed that Baicalin could inhibit TH17 cell differentiation
in complete Freund’s adjuvant induced inflammatory arthropathy
mice, and ovalbumin immunized mice. Together, these data suggest
that Baicalin could inhibit TH1 7c e l ld i f f e r e n t i a t i o ni nv i v o ,a n de x e r t
therapeutic effects via inhibition of IL-17-mediated inflammation.
Our findings define a role of Baicalin in TH17 lineage
commitment, thereby linking this natural compound to adaptive
immunity in a way that has important implications for immune
homeostasis and inflammatory diseases. Taken together, these
findings suggest that Baicalin might be a promising therapeutic
agent for the treatment of TH17 cells-mediated inflammatory
diseases.
Figure 5. Baicalin inhibits IL-17
+ lymphocyte infiltration into kidney. (A) IL-17 immunohistochemical staining in kidneys from MRL/lpr mice
treated with Baicalin or vehicle for 9 weeks, arrow shows the typical IL-17
+ lymphocytes. Scale bar, 100 mm. Five independent microscopic fields were
selected randomly for each sample to ensure representativeness and homogeneity. Right panel shows the IL-17
+ cells counted under 6100
magnification. (B) CCL20 mRNA expression in kidney. (C) CD4
+CD25
2 T cells from B6 mice were cultured under TH17 conditions with or without
Baicalin for 3 days, CCR6 mRNA expression in TH17 cells was examined by RT-PCR. These experiments were performed three times with similar results.
doi:10.1371/journal.pone.0017164.g005
Control of TH17 Cell Differentiation by Baicalin
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17164Methods
Plasmids, cell lines, and transfection
The Foxp3-IRES-GFP expression plasmid (pZIGF) and control
plasmid were kindly provided by Wang Shengjun. TH17 cells were
transiently transfected by electroporation according to the manu-
facturer’s protocol (Eppendorf, Hamburg, Germany). 48 hours
after transfection, RORct, IL-17, and Foxp3 mRNA expression
were examined by RT-PCR. Human umbilical vein endothelial cell
(HUVEC) line was maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Hyclone, Logan, UT). Jurkat cells were
maintained in RPMI 1640 medium (Gibco, Grand Island, NY).
Mice and histopathology
C57BL/6 (B6) and lupus-prone MRL/lpr mice were purchased
from the Shanghai Laboratory Animal Center (Chinese Academy
of Sciences). The animal study was approved by the institutional
animal care and use committee of Zhongshan Hospital, Fudan
University (ZS0862701). All mice were maintained under
pathogen-free conditions. The onset of autoimmune diseases in
MRL/lpr mice was monitored by the assessment of proteinuria.
After clinical onset of disease, Baicalin (100 mg/kg; Purity.98%,
National Institute for the Control of Pharmaceutical and
Biological Products, Beijing, China; Baicalin was dissolved in
phosphate-buffered saline prior to experimentation.) or PBS
vehicle was given intraperitoneally every day for 9 weeks. For
detection of urine protein, the total urine of 24 h were first
collected, and performed according to the manufacturer’s
directions (Roche). Relative urine protein increases = urine
protein (mg/L) at indicated time point - urine protein (mg/L) of
week 0. At the time of sacrifice (9 weeks after treatment), the
kidneys were fixed with formaldehyde, embedded in paraffin,
stained with hematoxylin and eosin (H&E), and IL-17 (Santa Cruz
Biotechnology, CA).
Figure 6. Baicalin inhibits IL-17 mediated gene expression of inflammatory molecules. (A) HUVEC was cultured in the presence of 50
ng/ml IL-17 in the presence or absence of Baicalin for 24 hours. Expression of the indicated genes was examined by RT-PCR. (B) HUVEC was
stimulated in the presence of IL-17 with or without Baicalin for 24 hours. Jurkat cells were added for an additional 24 hours. After washing twice, the
adhesive cells were counted under 6200 magnifications. Five independent microscopic fields were selected randomly for each sample to ensure
representativeness and homogeneity. Results were expressed as mean 6 SD. Arrows indicate the adhesive cells. Scale bar, 100 mm. These
experiments were performed three times with similar results.
doi:10.1371/journal.pone.0017164.g006
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grading the kidneys for glomerular inflammation, proliferation,
crescent formation, and necrosis. Interstitial changes and vasculitis
were also noted. Scores from 0 to 3 were assigned for each of these
features and then added together to yield a final renal scores. For
example, glomerular inflammation was graded: 0, normal; 1, few
inflammatory cells; 2, moderate inflammation; and 3, severe
inflammation. Detailed pathological assessment was performed as
described previously [52]. The spleens of MRL/lpr mice were
collected to calculate the spleen index. Spleen index = spleen
weight (g) divided by body weight (g).
CD4
+ T cell isolation, culture conditions, and western blot
CD4
+CD25
2 T cells from B6 mice spleens were isolated by
fluorescence activated cell sorting (FACS). T cells were stimulated
with 2 mg/ml plate-bound anti-CD3e (clone:17A2) and 2 mg/ml
soluble anti-CD28 (clone: 37.51; eBioscience, San Diego, CA) for
the indicted number of days. Where indicated, cultures were
supplemented with 5 ng/ml TGF-b, 20 ng/ml IL-6 (PeproTech,
RockyHill, NJ), and 20 mM Baicalin (Baicalin was dissolved in
DMSO), and DMSO vehicle control was used in some
experiments. For some experiments, CD4
+CD25
2 T cells were
cultured under TH17 culture conditions (TGF-b plus IL-6
stimulation) for 2 days, and then transfected with Foxp3 expression
plasmids by electroporation. For detection of IL-6R protein,
CD4
+CD25
2 T cells were cultured under TH17 culture conditions
with or without 20 mM Baicalin for 2 days, monoclonal anti-IL-6R
was used to detect the protein expression of IL-6R (Santa Cruz),
and b-actin was used as internal control (Santa Cruz).
Intracellular cytokine staining and flow cytometry
analysis
For detection of TH17 cells, cells obtained from in vitro cultures
or spleen cells from mice were incubated for 5 hours with 50
ng/ml phorbol myristate acetate (PMA) and 750 ng/ml ionomy-
cin in the presence of 20 mg/ml brefeldin A (Sigma-Aldrich) in a
tissue culture incubator at 37uC. Surface staining with FITC-
conjugated anti-CD4 (eBioscience) was first performed for 15 min,
then cells were re-suspended in Fixation/Permeabilization solution
according to the manufacturer’s instructions (Invitrogen), intra-
cellular staining of PE-conjugated anti-IL-17 or isotype control
was performed according to the manufacturer’s protocol
(eBioscience). After staining, we first gated on CD4
+ T cells, then
CD4
+IL-17
+ cells were analyzed in a CD4
+ gate in a FACS-
Calibur (BD-Bioscience, Biosciences, San Jose, CA), and followed
by analysis with FlowJo software (Tree Star, San Carlos, CA).
For detection of Treg cells, cells were treated according to the
Foxp3-staining kit protocol (eBioscience). Gating was on CD4
+ T
cells first, and then Foxp3
+ cells were analyzed in CD4
+ gate.
Cytokine production
Sorted CD4
+CD25
2 T cells from B6 mice were cultured under
neutral conditions or in the presence of 5 ng/ml TGF-b plus
20 ng/ml IL-6 with or without 20 mM Baicalin for 3 days. IL-17
concentrations were determined by ELISA (R&D Systems,
Minneapolis, MN).
HUVEC and T cell co-culture
HUVEC was seeded into 12-well plates (10,000 cells/well) and
allowed to adhere for 24 hours. Then HUVEC was stimulated
with 50 ng/ml IL-17 (eBioscience) for 24 hours with or without
20 mM Baicalin. After stimulation, Jurkat cells were added to the
HUVEC cultures at a 1:5 ratio, and the co-culture was extended
for an additional 24 hours. The HUVEC was then washed twice
to eliminate the non-adherent Jurkat cells. The adhesion of T cells
was counted under 6200 magnification.
RNA isolation and real-time RT-PCR
Total RNA was prepared with the use of the Trizol reagent
(Invitrogen). The cDNA was synthesized with a first-strand cDNA
synthesis kit and oligo (dT) primers (Fermentas, Hanover, MD),
and gene expression was examined with a Bio-Rad iCycler Optical
System (Bio-Rad, Richmond, CA) using a SYBR green real-time
PCR Master Mix (Toyobo, Osaka, Japan). The 2
2DDCt method
was used to normalize transcription to human 18S or mus b-actin
and calculate fold induction relative to controls. The primer pairs
could be seen in Table 2.
Statistical analysis
The quantitative data were expressed as the means 6
standard deviation (SD). The statistical significance was
determined by ANOVA followed by Bonferroni post-hoc test
for multiple comparisons or the Student’s t-test. A paired t-test
was also used in some cases. All p values #0.05 were considered
significant.
Table 2. The following primer pairs were used.
Gene Forward (59-39) Reverse (59-39)
Mus RORct CCGCTGAGAGGGCTTCAC TGCAGGAGTAGGCCACATTACA
Mus b-actin GACGGCCAGGTCATCACTATTG AGGAAGGCTGGAAAAGAGCC
Mus Foxp3 CCCAGGAAAGACAGCAACCTT TTCCACAACAAGGCCACTTG
Mus IL-17A CTCCAGAAGGCCCTCAGACTCA GGGTCTTCATTGCGGTGG
Mus IL-6 receptor GCAAGTCCAGCCACAACG ACTCGGGTCCCAGGTCTCA
Mus CCR6 GTGGTGTATGAGAAGGAAGAATAAGATG GTCTGCCTGGAGATGTAGCTTTC
Mus CCL20 CTGATGCTTTTTTGGGATGGA CCCCAGCTGTGATCATTTCC
Human ICAM-1 ATCTGTGTCCCCCTCAAAAG GGTCTCTATGCCCAACAACT
Human VCAM-1 TACAACCGTCTTGGTCAGCC CCACAGGATTTTCGGAGCA
Human 18S GCCCGAAGCGTTTACTTTGA TCCATTATTCCTAGCTGCGGTATC
Human IL-17 AAAGTGGCCCGGATGTGAGA GACATTGTGCCCTGCCCTTCT
doi:10.1371/journal.pone.0017164.t002
Control of TH17 Cell Differentiation by Baicalin
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e17164Supporting Information
Figure S1 Baicalin does not inhibit T cell proliferation.
(A) Chemical structure of Baicalin. (B) FACS-sorted naı ¨ve
CD4
+CD25
2 T cells from B6 mice were stimulated with anti-
CD3 and anti-CD28 in the presence of indicated doses of Baicalin
for 3 days. Cell proliferation was measured by MTT. (C) Cell cycle
was analyzed by flow cytometry. These experiments were
performed three times with similar results.
(TIF)
Figure S2 Baiclain does not affect IL-23R, IL-21R, and
other cytokines mRNA expression. (A) FACS-sorted
CD4
+CD25
2 T cells from B6 mice were stimulated with TGF-b
and IL-6 in the presence of absence of Baicalin for 2 days. IL-23R,
IL-21R, STAT3, IL-4R, and IL-12Rb2 mRNA expression were
examined by RT-PCR. (B) FACS-sorted CD4
+CD25
2 T cells
from B6 mice were stimulated with TGF-b and IL-21 in the
presence or absence of Baicalin for 2 days. STAT3, IL-17, and
Foxp3 mRNA expression were examined by RT-PCR. (C) FACS-
sorted CD4
+CD25
2 T cells from B6 mice were stimulated with
TGF-b and IL-21 in the presence or absence of Baicalin for 3
days, IL-17 and STAT3 mRNA expression were examined by
real-time RT-PCR. (D) FACS-sorted CD4
+CD25
2 T cells from
B6 mice were stimulated with TGF-b and IL-6 in the presence or
absence of Baicalin for 24h, Stat3 phosphorylation was analyzed
by FACS. These experiments were performed three times with
similar results.
(TIF)
Figure S3 Baicalin promotes Foxp3 mRNA and inhibit
RORct-mediated IL-17 mRNA expression in vitro. (A)
CD4
+CD25
2 T cells from B6 mice were cultured under TH17
conditions for 2 days and then transiently transfected with control
plasmids (Control) or RORct expression plasmids (RORct) in the
presence or absence of Baicalin. 2 days later, IL-17 mRNA was
examined by RT-PCR. (B) FACS-sorted CD4
+CD25
2 T cells
from B6 mice were stimulated with TGF-b and/or Baicalin for 3
days. Foxp3 mRNA expression was examined by real-time RT-
PCR. Results were expressed as mean 6 SD, and fold induction
compared with vehicle control (expression in vehicle control was
set as 1.0). These experiments were performed three times with
similar results.
(TIF)
Figure S4 Baicalin protects the liver function of MRL/
lpr mice. (A) MRL/lpr mice were treated with Baicalin or
vehicle for 9 weeks, B6 mice (control) were treated with vehicle.
Alanine aminotransferase (ALT) in serum was checked (n=6 for
each group). Results were expressed as mean 6 SD. (B) Aspartate
aminotransferase (AST) in serum was checked (n=6 for each
group). Results were expressed as mean 6 SD.
(TIF)
Figure S5 Baicalin inhibits the gene expression of
inflammatory mediators in vivo. The gene expression of
inflammatory mediators in kidneys of MRL/lpr mice treated with
Baicalin or vehicle for 9 weeks was analyzed by RT-PCR. These
experiments were performed three times with similar results.
(TIF)
Figure S6 20mM Baicalin does not affect IFN-c and IL-4
mRNA expression. CD4
+CD25
2 T cells from B6 mice were
stimulated with anti-CD3, anti-CD28, and the indicated cytokines
in the presence or absence of Baicalin for 3 days. IFN-c and IL-4
mRNA expression were analyzed by RT-PCR. These experiments
were performed three times with similar results.
(TIF)
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